Drug Trial Radar · NCT07388602
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Conditions
- Amyloidosis
Interventions
SCTC21CDrug
Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous
BortezomibDrug
Pharmaceutical form: Lyophilized powder for injection; Route of administration: Subcutaneous
DexamethasoneDrug
Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous
CyclophosphamideDrug
Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Overall Complete Hematologic Response (CHR)Time frame: Up to approximately 50 months after the First Participant In (FPI)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.